Brain disorders, such as brain cancer and neuroinflammatory diseases, can be devastating for patients and their families. However, to-BBB, a clinical-stage biotechnology company, is developing novel treatments that combine existing drugs with their proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. With two products in clinical trials, to-BBB is at the forefront of innovative solutions for brain disorders.
Developing Novel Treatments for Brain Disorders
to-BBB is a biotechnology company based in the Netherlands that is developing novel treatments for brain disorders. The company’s focus is on enhancing drug delivery across the blood-brain barrier, which is a major obstacle in the treatment of brain disorders. By combining existing drugs with to-BBB’s proprietary G-Technology®, the company is able to enhance drug delivery and improve the efficacy of treatments for brain disorders.
Two Products in Clinical Trials
to-BBB currently has two products in clinical trials. Its lead product, 2B3-101, is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases. The second product, 2B3-201, is completing a Phase I clinical study and is designed for the treatment of MS relapses and other neuroinflammatory diseases. These products have the potential to revolutionize the treatment of brain disorders by improving drug delivery across the blood-brain barrier.
Headquartered in the Netherlands with a Subsidiary in Taiwan
to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park, which is one of the leading life sciences clusters in Europe. The company has also established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. This global presence allows the company to collaborate with partners and investors around the world to advance its research and development efforts.
Investors in to-BBB
to-BBB has received support from a range of investors, including Aescap Venture, Antea Participaties, Jonghoud International, and the Industrial Bank of Taiwan Management Corporation (IBTM). These investors recognize the potential of to-BBB’s technology and are committed to supporting the company as it develops new treatments for brain disorders.
In conclusion, to-BBB is a clinical-stage biotechnology company that is developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. By combining existing drugs with to-BBB’s proprietary G-Technology®, the company is able to enhance drug delivery across the blood-brain barrier and improve the efficacy of treatments. With two products in clinical trials and a global presence, to-BBB is at the forefront of innovative solutions for brain disorders. Check out to-BBB’s website and social media channels to learn more.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!